<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">ometendo</journal-id><journal-title-group><journal-title xml:lang="ru">Ожирение и метаболизм</journal-title><trans-title-group xml:lang="en"><trans-title>Obesity and metabolism</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2071-8713</issn><issn pub-type="epub">2306-5524</issn><publisher><publisher-name>Endocrinology Research Centre</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.14341/2071-8713-5049</article-id><article-id custom-type="elpub" pub-id-type="custom">ometendo-5049</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>Статьи</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>Articles</subject></subj-group></article-categories><title-group><article-title>Перспективы применения селективного модулятора эстрогеновых рецепторов тамоксифена в нейроэндокринологии</article-title><trans-title-group xml:lang="en"><trans-title>Prospects for the use of selective estrogen receptor modulator tamoxifen</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Bykanova</surname><given-names>N S</given-names></name></name-alternatives><email xlink:type="simple">bykanova@gmail.com</email></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Pigarova</surname><given-names>E A</given-names></name></name-alternatives><email xlink:type="simple">kpigarova@gmail.com</email></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Dzeranova</surname><given-names>L K</given-names></name></name-alternatives><email xlink:type="simple">metabol@endocrincentr.ru</email></contrib></contrib-group><pub-date pub-type="collection"><year>2012</year></pub-date><pub-date pub-type="epub"><day>15</day><month>03</month><year>2012</year></pub-date><volume>9</volume><issue>1</issue><issue-title>№1 (2012)</issue-title><fpage>9</fpage><lpage>13</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Bykanova N.S., Pigarova E.A., Dzeranova L.K., 2012</copyright-statement><copyright-year>2012</copyright-year><copyright-holder xml:lang="ru">Bykanova N.S., Pigarova E.A., Dzeranova L.K.</copyright-holder><copyright-holder xml:lang="en">Bykanova N.S., Pigarova E.A., Dzeranova L.K.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.omet-endojournals.ru/jour/article/view/5049">https://www.omet-endojournals.ru/jour/article/view/5049</self-uri><abstract><p>В обзоре литературы представлены сведения о применении тамоксифена при различных патологиях головного мозга, механизмах нейропротективного действия селективных модуляторов эстрогеновых рецепторов. Рассмотрены вопросы применения тамоксифена при аденомах гипофиза, в частности, пролактиномах, его влияния на репродуктивную функцию женщин, риск развития осложнений беременности, пороков развития у плода, если у женщины наступила беременность во время приема препарата, а также основания для прекращения терапии тамоксифеном до беременности.</p></abstract><trans-abstract xml:lang="en"><p>The review presents a contemporary data concerning the use of tamoxifen in wide range of pathological conditions: central nervous system diseases and mechanisms of neuroprotective action of estrogen receptors, pituitary tumors with the accent on the treatment of prolactinomas, infertility treatment. We also discuss the risks of tamoxifen treatment for pregnancy induction in women including complications of pregnancy, fetus malformations.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>тамоксифен</kwd><kwd>беременность</kwd><kwd>нервная система</kwd><kwd>аденома гипофиза</kwd><kwd>ановуляция</kwd></kwd-group><kwd-group xml:lang="en"><kwd>tamoxifen</kwd><kwd>pregnancy</kwd><kwd>nervous system</kwd><kwd>pituitary adenoma</kwd><kwd>anovulation</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Adami HO, Malker B, Holmberg L, Persson I, Stone B. The relation between survival and age at diagnosis in breast cancer. N Engl J Med 1986; 315: 559-63.</mixed-citation><mixed-citation xml:lang="en">Adami HO, Malker B, Holmberg L, Persson I, Stone B. The relation between survival and age at diagnosis in breast cancer. N Engl J Med 1986; 315: 559-63.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Barthelmes L, CA Gateley. Tamoxifen and pregnancy. The Breast 2004; 13(6): 446-51.</mixed-citation><mixed-citation xml:lang="en">Barthelmes L, CA Gateley. Tamoxifen and pregnancy. The Breast 2004; 13(6): 446-51.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Bebo BF, Dehghani B, Foster S, Kurniawan A, Lopez FJ &amp;amp; Sherman LS Treatment with selective estrogen receptor modulators regulates myelin specific T-cells and suppresses experimental autoimmune encephalomielits. Glia 2009; 57: 777-90.</mixed-citation><mixed-citation xml:lang="en">Bebo BF, Dehghani B, Foster S, Kurniawan A, Lopez FJ &amp;amp; Sherman LS Treatment with selective estrogen receptor modulators regulates myelin specific T-cells and suppresses experimental autoimmune encephalomielits. Glia 2009; 57: 777-90.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Bines J, Oleske DM, Cobleigh MA. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol 1996; 14: 1718-29.</mixed-citation><mixed-citation xml:lang="en">Bines J, Oleske DM, Cobleigh MA. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol 1996; 14: 1718-29.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Bourque M, Liu B, Dluzen DE &amp;amp; Di Paolo T. Tamoxifen protects male mice nigrostriatal dopamine against methamphetamine-induced toxicity. Biochemical Pharmacology 2007; 74: 1413-23.</mixed-citation><mixed-citation xml:lang="en">Bourque M, Liu B, Dluzen DE &amp;amp; Di Paolo T. Tamoxifen protects male mice nigrostriatal dopamine against methamphetamine-induced toxicity. Biochemical Pharmacology 2007; 74: 1413-23.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Breuer B &amp;amp; Anderson R. The relationship of tamoxifen with dementia, depression, and dependence in activities of daily living in elderly nursing home residents. Women's Health 2000; 31: 71-85.</mixed-citation><mixed-citation xml:lang="en">Breuer B &amp;amp; Anderson R. The relationship of tamoxifen with dementia, depression, and dependence in activities of daily living in elderly nursing home residents. Women's Health 2000; 31: 71-85.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Briggs GG, Freeman RK, Yaffe SJ. Drugs in pregnancy and lactation, 6th ed. Philadelphia: Williams &amp;amp; Wilkins 2002: 1307-313.</mixed-citation><mixed-citation xml:lang="en">Briggs GG, Freeman RK, Yaffe SJ. Drugs in pregnancy and lactation, 6th ed. Philadelphia: Williams &amp;amp; Wilkins 2002: 1307-313.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Burdman JA, Pauni M, Heredia Sereno GM, Bordon AE. Estrogen receptors in human pituitary tumors. Horm Metab Res 2008; 40(8): 524-7.</mixed-citation><mixed-citation xml:lang="en">Burdman JA, Pauni M, Heredia Sereno GM, Bordon AE. Estrogen receptors in human pituitary tumors. Horm Metab Res 2008; 40(8): 524-7.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Chaidarun SS, Klibanski A, Alexander JM. Tumor-specific expression of alternatively spliced estrogen receptor messenger ribonucleic acid variants in human pituitary adenomas. J Clin Endocrinol Metab 1997; 82: 1058-65.</mixed-citation><mixed-citation xml:lang="en">Chaidarun SS, Klibanski A, Alexander JM. Tumor-specific expression of alternatively spliced estrogen receptor messenger ribonucleic acid variants in human pituitary adenomas. J Clin Endocrinol Metab 1997; 82: 1058-65.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Changhai H, Youlun G, Jie Y, et al. A randomized comparative study on mifepristone alone and in combination with tamoxifen for emergency contraception. Contraception 2002; 66: 221-4.</mixed-citation><mixed-citation xml:lang="en">Changhai H, Youlun G, Jie Y, et al. A randomized comparative study on mifepristone alone and in combination with tamoxifen for emergency contraception. Contraception 2002; 66: 221-4.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Clark S. Prophylactic tamoxifen. Lancet 1993; 342: 168.</mixed-citation><mixed-citation xml:lang="en">Clark S. Prophylactic tamoxifen. Lancet 1993; 342: 168.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Colao A: Pituitary tumours: the prolactinoma. Best Pract Res Clin Endocrinol Metab 2009; 23: 575-96.</mixed-citation><mixed-citation xml:lang="en">Colao A: Pituitary tumours: the prolactinoma. Best Pract Res Clin Endocrinol Metab 2009; 23: 575-96.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Cullins SL, Pridjian G, Sutherland CM. Goldenhar's syndrome associated with tamoxifen given to the mother during gestation. J Am Med Assoc 1994; 271(24): 1905-6.</mixed-citation><mixed-citation xml:lang="en">Cullins SL, Pridjian G, Sutherland CM. Goldenhar's syndrome associated with tamoxifen given to the mother during gestation. J Am Med Assoc 1994; 271(24): 1905-6.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Cunha GR, Taguchi O, Namikawa R, Nishizuka Y, Robboy SJ. Teratogenic effects of tamoxifen on the developing human female genital tract. Hum Pathol 1987; 18: 1132-43.</mixed-citation><mixed-citation xml:lang="en">Cunha GR, Taguchi O, Namikawa R, Nishizuka Y, Robboy SJ. Teratogenic effects of tamoxifen on the developing human female genital tract. Hum Pathol 1987; 18: 1132-43.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Debess J, Riis J, Engebjerg MC &amp;amp; Ewertz M. Cognitive function after adjuvant treatment for early breast cancer: a population-based longitudinal study. Breast Cancer Research and Treatment 2010; 121: 91-100.</mixed-citation><mixed-citation xml:lang="en">Debess J, Riis J, Engebjerg MC &amp;amp; Ewertz M. Cognitive function after adjuvant treatment for early breast cancer: a population-based longitudinal study. Breast Cancer Research and Treatment 2010; 121: 91-100.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Einat H, Yuan P, Szabo ST, Dogra S &amp;amp; Manji HK. Protein kinase C inhibition by tamoxifen antagonizes manic-like behavior in rats: implications for the development of novel therapeutics for bipolar disorder. Neuropsychobiology 2007; 55: 123-31.</mixed-citation><mixed-citation xml:lang="en">Einat H, Yuan P, Szabo ST, Dogra S &amp;amp; Manji HK. Protein kinase C inhibition by tamoxifen antagonizes manic-like behavior in rats: implications for the development of novel therapeutics for bipolar disorder. Neuropsychobiology 2007; 55: 123-31.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Friend KE, Chiou YK, Lopes MBS, Laws Jr ER, Hughes KM, Shupnik MA. Estrogen receptor expression in human pituitary: correlation with immunohistochemistry in normal tissue, and immunohistochemistry and morphology in macroadenomas. J Clin Endocrinol Metab 1994; 78: 1497-504.</mixed-citation><mixed-citation xml:lang="en">Friend KE, Chiou YK, Lopes MBS, Laws Jr ER, Hughes KM, Shupnik MA. Estrogen receptor expression in human pituitary: correlation with immunohistochemistry in normal tissue, and immunohistochemistry and morphology in macroadenomas. J Clin Endocrinol Metab 1994; 78: 1497-504.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Gillam MP, Molitch ME, Lombardi G, Colao A: Advances in the treatment of prolactinomas. Endocr Rev 2006; 27: 485-534.</mixed-citation><mixed-citation xml:lang="en">Gillam MP, Molitch ME, Lombardi G, Colao A: Advances in the treatment of prolactinomas. Endocr Rev 2006; 27: 485-534.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Hines M, Alsum P, Gorski RA, Goy RW. Estrogenic contributions to sexual differentiation in the female guinea pig: influences of dethylstilbestrol and tamoxifen on neural, behavioral and ovarian development. Horm Behav 1987; 21: 402-17.</mixed-citation><mixed-citation xml:lang="en">Hines M, Alsum P, Gorski RA, Goy RW. Estrogenic contributions to sexual differentiation in the female guinea pig: influences of dethylstilbestrol and tamoxifen on neural, behavioral and ovarian development. Horm Behav 1987; 21: 402-17.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">IBIS investigators. First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet 2002; 360: 817-24.</mixed-citation><mixed-citation xml:lang="en">IBIS investigators. First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet 2002; 360: 817-24.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Isaacs RJ, Hunter W, Clark K. Tamoxifen as systemic treatment of advanced breast cancer during pregnancy- case report and literature review. Gynecol Oncol 2001; 80(3): 405-8.</mixed-citation><mixed-citation xml:lang="en">Isaacs RJ, Hunter W, Clark K. Tamoxifen as systemic treatment of advanced breast cancer during pregnancy- case report and literature review. Gynecol Oncol 2001; 80(3): 405-8.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Jain JK, Meckstroth KR, Park M, Mishell Jr DR. A comparison of tamoxifen and misoprostol to misoprostol alone for early pregnancy termination. Contraception 1999; 60(6): 353-6.</mixed-citation><mixed-citation xml:lang="en">Jain JK, Meckstroth KR, Park M, Mishell Jr DR. A comparison of tamoxifen and misoprostol to misoprostol alone for early pregnancy termination. Contraception 1999; 60(6): 353-6.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Kaptain GJ, Simmons NE, Alden TD, Lopes MB, Vance ML, Laws ER. Estrogen receptors in prolactinomas: a clinico-pathological study. Pituitary 1999; 1(2): 91-8.</mixed-citation><mixed-citation xml:lang="en">Kaptain GJ, Simmons NE, Alden TD, Lopes MB, Vance ML, Laws ER. Estrogen receptors in prolactinomas: a clinico-pathological study. Pituitary 1999; 1(2): 91-8.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Koizumi K, Aono T. Pregnancy after combined treatment with bromocriptine and tamoxifen in two patients with pituitary prolactinomas. Fertil Steril 1986; 46(2): 312-4.</mixed-citation><mixed-citation xml:lang="en">Koizumi K, Aono T. Pregnancy after combined treatment with bromocriptine and tamoxifen in two patients with pituitary prolactinomas. Fertil Steril 1986; 46(2): 312-4.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Lamberts SW, de Quijada M, Klijn JG. The effect of tamoxifen on GH and PRL secretion by human pituitary tumors. J Endocrinol Invest 1980; 3(4): 343-7.</mixed-citation><mixed-citation xml:lang="en">Lamberts SW, de Quijada M, Klijn JG. The effect of tamoxifen on GH and PRL secretion by human pituitary tumors. J Endocrinol Invest 1980; 3(4): 343-7.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Lee ES, Sidoryk M, Jiang H, Yin Z &amp;amp; Aschner M. Estrogen and tamoxifen reverse manganese-induced glutamate transporter impairment in astrocytes. Journal of Neurochemistry 2009; 110: 530-544.</mixed-citation><mixed-citation xml:lang="en">Lee ES, Sidoryk M, Jiang H, Yin Z &amp;amp; Aschner M. Estrogen and tamoxifen reverse manganese-induced glutamate transporter impairment in astrocytes. Journal of Neurochemistry 2009; 110: 530-544.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Liebens E, Carly B, Pastijn A, Fastrez M, Vandromme J. Desire for a child and breast cancer. Acta Chir Belg 2008 Jan-Feb; 108(1): 83-7.</mixed-citation><mixed-citation xml:lang="en">Liebens E, Carly B, Pastijn A, Fastrez M, Vandromme J. Desire for a child and breast cancer. Acta Chir Belg 2008 Jan-Feb; 108(1): 83-7.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Manoranjan B, Salehi F, Scheithauer BW, Rotondo F, Kovacs K, Cusimano MD. Estrogen receptors alpha and beta immunohistochemical expression: clinicopathological correlations in pituitary adenomas. Anticancer Res 2010; 30(7): 2897-904.</mixed-citation><mixed-citation xml:lang="en">Manoranjan B, Salehi F, Scheithauer BW, Rotondo F, Kovacs K, Cusimano MD. Estrogen receptors alpha and beta immunohistochemical expression: clinicopathological correlations in pituitary adenomas. Anticancer Res 2010; 30(7): 2897-904.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Mehta DK, editor. Pregnancy. British National Formulary No. 45. London: British Medical Association and Royal Pharmaceutical Society 2004: 726 [Appendix 4].</mixed-citation><mixed-citation xml:lang="en">Mehta DK, editor. Pregnancy. British National Formulary No. 45. London: British Medical Association and Royal Pharmaceutical Society 2004: 726 [Appendix 4].</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Michael C. Oh, M.D., Ph.D., and Manish K. Aghi, M.D., Ph.D. Dopamine agonist-resistant prolactinomas. J Neurosurg 2011; 114: 1369-79.</mixed-citation><mixed-citation xml:lang="en">Michael C. Oh, M.D., Ph.D., and Manish K. Aghi, M.D., Ph.D. Dopamine agonist-resistant prolactinomas. J Neurosurg 2011; 114: 1369-79.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Mishell Jr. DR, Jain JK, Byrne JD, Lacarra MD. A medical method of early pregnancy termination using tamoxifen and misoprostol. Contraception 1998; 58(1): 1-6.</mixed-citation><mixed-citation xml:lang="en">Mishell Jr. DR, Jain JK, Byrne JD, Lacarra MD. A medical method of early pregnancy termination using tamoxifen and misoprostol. Contraception 1998; 58(1): 1-6.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Monson JP: The epidemiology of endocrine tumours. Endocr Relat Cancer 2000; 7: 29-36.</mixed-citation><mixed-citation xml:lang="en">Monson JP: The epidemiology of endocrine tumours. Endocr Relat Cancer 2000; 7: 29-36.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Morissette M, Al Sweidi S, Callier S &amp;amp; Di Paolo T. Estrogen and SERM neuroprotection in animal models of Parkinson's disease. Molecular and Cellular Endocrinology 2008; 290: 60-69.</mixed-citation><mixed-citation xml:lang="en">Morissette M, Al Sweidi S, Callier S &amp;amp; Di Paolo T. Estrogen and SERM neuroprotection in animal models of Parkinson's disease. Molecular and Cellular Endocrinology 2008; 290: 60-69.</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Oksuzoglu B, Guler N. An infertile patient with breast cancer who delivered a healthy child under adjuvant tamoxifen therapy. Eur J Obstet Gynecol Reprod Biol 2002; 104(1): 79.</mixed-citation><mixed-citation xml:lang="en">Oksuzoglu B, Guler N. An infertile patient with breast cancer who delivered a healthy child under adjuvant tamoxifen therapy. Eur J Obstet Gynecol Reprod Biol 2002; 104(1): 79.</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Oktay K, Buyuk E, Davis O, Yermakova I, Veeck L, Rosenwaks Z. Fertility preservation in breast cancer patients: IVF and embryo cryopreservation after ovarian stimulation with tamoxifen. Hum Reprod. 2003; 18(1): 90.</mixed-citation><mixed-citation xml:lang="en">Oktay K, Buyuk E, Davis O, Yermakova I, Veeck L, Rosenwaks Z. Fertility preservation in breast cancer patients: IVF and embryo cryopreservation after ovarian stimulation with tamoxifen. Hum Reprod. 2003; 18(1): 90.</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Pinchon MF, Bression D, Peillon F, Milgrom E. Estrogen receptors in human pituitary adenomas. J Clin Endocrinol Metab. 1980; 51: 897-902.</mixed-citation><mixed-citation xml:lang="en">Pinchon MF, Bression D, Peillon F, Milgrom E. Estrogen receptors in human pituitary adenomas. J Clin Endocrinol Metab. 1980; 51: 897-902.</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Physicians' Desk Reference Health; Nolvadex; 2003. Accessed July 15, 2004, at http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/nol1299.shtml</mixed-citation><mixed-citation xml:lang="en">Physicians' Desk Reference Health; Nolvadex; 2003. Accessed July 15, 2004, at http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/nol1299.shtml</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Pugh DM, Sumano HS. The anti-implantation action of tamoxifen in mice. Arch Toxicol 1982; 5(Suppl.): 209-13.</mixed-citation><mixed-citation xml:lang="en">Pugh DM, Sumano HS. The anti-implantation action of tamoxifen in mice. Arch Toxicol 1982; 5(Suppl.): 209-13.</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Schilder CM, Seynaeve C, Beex LV, Boogerd W, Linn SC, Gundy CM, Huizenga HM, Nortier JW, van de Velde CJ, van Dam FS et al. Effects of tamoxifen and exemestane on cognitive functioning of postmenopausal patients with breast cancer: results from the neuropsychological side study of the tamoxifen and exemestane adjuvant multinational trial. Journal of Clinical Oncology 2010; 28: 1294-1300.</mixed-citation><mixed-citation xml:lang="en">Schilder CM, Seynaeve C, Beex LV, Boogerd W, Linn SC, Gundy CM, Huizenga HM, Nortier JW, van de Velde CJ, van Dam FS et al. Effects of tamoxifen and exemestane on cognitive functioning of postmenopausal patients with breast cancer: results from the neuropsychological side study of the tamoxifen and exemestane adjuvant multinational trial. Journal of Clinical Oncology 2010; 28: 1294-1300.</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">Shupnik M.A., Pitt L.K., Soh A.Y., Anderson A., Lopes M.B., Laws E.R. Selective Expression of Estrogen Receptor α and β Isoforms in Human Pituitary Tumors. J Clin Endocrinol Metab 1998; 83(11): 3965-72.</mixed-citation><mixed-citation xml:lang="en">Shupnik M.A., Pitt L.K., Soh A.Y., Anderson A., Lopes M.B., Laws E.R. Selective Expression of Estrogen Receptor α and β Isoforms in Human Pituitary Tumors. J Clin Endocrinol Metab 1998; 83(11): 3965-72.</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">Tewari K, Bonebrake RG, Asrat T, Shanberg AM. Ambiguous genitalia in infant exposed to tamoxifen in utero. Lancet. 1997; 350(9072): 183.</mixed-citation><mixed-citation xml:lang="en">Tewari K, Bonebrake RG, Asrat T, Shanberg AM. Ambiguous genitalia in infant exposed to tamoxifen in utero. Lancet. 1997; 350(9072): 183.</mixed-citation></citation-alternatives></ref><ref id="cit42"><label>42</label><citation-alternatives><mixed-citation xml:lang="ru">Tian DS, Liu JL, Xie MJ, Zhan Y, Qu WS, Yu ZY, Tang ZP, Pan DJ &amp;amp; Wang W. Tamoxifen attenuates inflammatory-mediated damage and improves functional outcome after spinal cord injury in rats. Journal of Neurochemistry 2009; 109: 1658-67.</mixed-citation><mixed-citation xml:lang="en">Tian DS, Liu JL, Xie MJ, Zhan Y, Qu WS, Yu ZY, Tang ZP, Pan DJ &amp;amp; Wang W. Tamoxifen attenuates inflammatory-mediated damage and improves functional outcome after spinal cord injury in rats. Journal of Neurochemistry 2009; 109: 1658-67.</mixed-citation></citation-alternatives></ref><ref id="cit43"><label>43</label><citation-alternatives><mixed-citation xml:lang="ru">Tucker MJ, Adam HK, Patterson JS. Tamoxifen. In: Laurence DR, McLean AEM, Wetherall M, editors. Safety testing of new drugs: laboratory predictions and clinical performance. London: Academic Press 1984: 125-61 [chapter 6].</mixed-citation><mixed-citation xml:lang="en">Tucker MJ, Adam HK, Patterson JS. Tamoxifen. In: Laurence DR, McLean AEM, Wetherall M, editors. Safety testing of new drugs: laboratory predictions and clinical performance. London: Academic Press 1984: 125-61 [chapter 6].</mixed-citation></citation-alternatives></ref><ref id="cit44"><label>44</label><citation-alternatives><mixed-citation xml:lang="ru">Völker W, Gehring WG, von zur Mühlen A, Schneider J. Bromocriptine and tamoxifen - a new therapeutic approach in suppression-resistant prolactin-secreting adenomas. Geburtshilfe Frauenheilkd 1982 Nov; 42(11): 790-7.</mixed-citation><mixed-citation xml:lang="en">Völker W, Gehring WG, von zur Mühlen A, Schneider J. Bromocriptine and tamoxifen - a new therapeutic approach in suppression-resistant prolactin-secreting adenomas. Geburtshilfe Frauenheilkd 1982 Nov; 42(11): 790-7.</mixed-citation></citation-alternatives></ref><ref id="cit45"><label>45</label><citation-alternatives><mixed-citation xml:lang="ru">Yamashita M, Hirakawa T, Tashiro Y, Matsuda T, Kibe M, Fukashima T, Tomonaga M. Effect of tamoxifen on the treatment of pituitary adenomas with bromocriptine. No Shinkei Geka 1987 Jan; 15(1): 65-72.</mixed-citation><mixed-citation xml:lang="en">Yamashita M, Hirakawa T, Tashiro Y, Matsuda T, Kibe M, Fukashima T, Tomonaga M. Effect of tamoxifen on the treatment of pituitary adenomas with bromocriptine. No Shinkei Geka 1987 Jan; 15(1): 65-72.</mixed-citation></citation-alternatives></ref><ref id="cit46"><label>46</label><citation-alternatives><mixed-citation xml:lang="ru">Zafar M, Ezzat S, Raymyar L, Pan N, Smyth HS, Asa SL. Cell-specific expression of estrogen receptor in the human pituitary and its adenomas. J Clin Endocrinol Metab 1995; 80: 3621-27.</mixed-citation><mixed-citation xml:lang="en">Zafar M, Ezzat S, Raymyar L, Pan N, Smyth HS, Asa SL. Cell-specific expression of estrogen receptor in the human pituitary and its adenomas. J Clin Endocrinol Metab 1995; 80: 3621-27.</mixed-citation></citation-alternatives></ref><ref id="cit47"><label>47</label><citation-alternatives><mixed-citation xml:lang="ru">Zarate CA, Singh JB, Carlson PJ, Quiroz J, Jolkovsky L, Luckenbaugh DA &amp;amp; Manji HK. Efficacy of a protein kinase C inhibitor (tamoxifen) in the treatment of acute mania: a pilot study. Bipolar Disorders 2007; 9: 561-70.</mixed-citation><mixed-citation xml:lang="en">Zarate CA, Singh JB, Carlson PJ, Quiroz J, Jolkovsky L, Luckenbaugh DA &amp;amp; Manji HK. Efficacy of a protein kinase C inhibitor (tamoxifen) in the treatment of acute mania: a pilot study. Bipolar Disorders 2007; 9: 561-70.</mixed-citation></citation-alternatives></ref><ref id="cit48"><label>48</label><citation-alternatives><mixed-citation xml:lang="ru">Zhang H, Xie M, SchoolsGP, Feustel PF,WangW, Lei T, KimelbergHK&amp;amp; Zhou M. Tamoxifen mediated estrogen receptor activation protects against early impairment of hippocampal neuron excitability in an oxygen/glucose deprivation brain slice ischemia model. Brain Research 2009; 1247: 196-211.</mixed-citation><mixed-citation xml:lang="en">Zhang H, Xie M, SchoolsGP, Feustel PF,WangW, Lei T, KimelbergHK&amp;amp; Zhou M. Tamoxifen mediated estrogen receptor activation protects against early impairment of hippocampal neuron excitability in an oxygen/glucose deprivation brain slice ischemia model. Brain Research 2009; 1247: 196-211.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
